Literature DB >> 16815492

Alterations in glutamine synthetase activity in rat skeletal muscle are associated with advanced age.

Carole Pinel1, Véronique Coxam, Michelle Mignon, Daniel Taillandier, Christine Cubizolles, Patrice Lebecque, Dominique Darmaun, Dominique Meynial-Denis.   

Abstract

OBJECTIVE: Glutamine synthetase (GS), a key enzyme in the production of glutamine, is preserved in skeletal muscle during early aging (<24 mo). Because the effects of advanced age on GS are unknown, we investigated the effect of advanced age (>24 mo) on GS activity in skeletal muscle. We hypothesized that advanced age would enhance muscle GS activity.
METHODS: Muscle GS activities were assessed in adult (8 mo), mature adult (15 mo), aged (20-22 mo), advanced age (25-27 mo), or very advanced age (29-32 mo) female Wistar rats. Male Wistar (6-27 mo) were used to investigate the effect of gender on this activity.
RESULTS: Glutamine synthetase activity remained low and unaltered in rats from 8 to 22 mo of age, as previously demonstrated. In contrast, GS activity was high ( approximately 75% of individual values were higher than the low value mean) in 25-mo to 27-mo-old rats. In very-old-aged rats (29-32 mo), approximately 55% of GS activity data points exhibited low values. Changes in GS protein content paralleled those in GS activities. In male rats, GS activity was also high ( approximately 80% of individual values were higher than the mean value of 6-mo to 19-mo-old rats) at the upper limit of life expectancy (27 mo).
CONCLUSION: There is enhanced GS activity in old female and male rats suggesting a greater need for glutamine. In some very old rats, low GS activity may be associated with longevity or reflect a limitation in glutamine production due to extremely advanced age per se.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815492     DOI: 10.1016/j.nut.2006.05.005

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  7 in total

1.  Long-term intermittent glutamine supplementation repairs intestinal damage (structure and functional mass) with advanced age: assessment with plasma citrulline in a rodent model.

Authors:  A M Beaufrère; N Neveux; P Patureau Mirand; C Buffière; G Marceau; V Sapin; L Cynober; D Meydinal-Denis
Journal:  J Nutr Health Aging       Date:  2014-11       Impact factor: 4.075

2.  Effect of intermittent glutamine supplementation on skeletal muscle is not long-lasting in very old rats.

Authors:  D Meynial-Denis; A-M Beaufrère; M Mignon; P Patureau Mirand
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

3.  AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle.

Authors:  Spencer G Miller; Paul S Hafen; Andrew S Law; Catherine B Springer; David L Logsdon; Thomas M O'Connell; Carol A Witczak; Jeffrey J Brault
Journal:  Metabolism       Date:  2021-08-13       Impact factor: 13.934

Review 4.  Glutamine metabolism in advanced age.

Authors:  Dominique Meynial-Denis
Journal:  Nutr Rev       Date:  2016-03-02       Impact factor: 7.110

5.  Metabolic signatures of muscle mass loss in an elderly Taiwanese population.

Authors:  Chi-Jen Lo; Yu-Shien Ko; Su-Wei Chang; Hsiang-Yu Tang; Cheng-Yu Huang; Yu-Chen Huang; Hung-Yao Ho; Chih-Ming Lin; Mei-Ling Cheng
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

6.  Keratinocytes as depository of ammonium-inducible glutamine synthetase: age- and anatomy-dependent distribution in human and rat skin.

Authors:  Lusine Danielyan; Sebastian Zellmer; Stefan Sickinger; Genrich V Tolstonog; Jürgen Salvetter; Ali Lourhmati; Dieter D Reissig; Cristoph H Gleiter; Rolf Gebhardt; Gayane Hrachia Buniatian
Journal:  PLoS One       Date:  2009-02-10       Impact factor: 3.240

7.  Effects of Huang-Lian-Jie-Du Decoction on Oxidative Stress and AMPK-SIRT1 Pathway in Alzheimer's Disease Rat.

Authors:  Xinru Gu; Haiyu Zhao; Junyi Zhou; Yanyan Zhou; Xiaolu Wei; Hongjie Wang; Baolin Bian; Jian Yang; Wei Ren; Nan Si
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-02       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.